Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology
Provectus Biopharmaceuticals (OTCQB: PVCT) has launched VisiRose, Inc., its first Founded Entity, focusing on commercializing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT) for treating infectious keratitis and serious eye infections. The University of Miami is a minority shareholder in VisiRose.
The treatment combines Provectus's pharmaceutical-grade Rose Bengal Sodium (RBS) API with a light-based medical device developed at the Ophthalmic Biophysics Center at Bascom Palmer Eye Institute. RB PDAT is designed to treat eye infections caused by bacteria, fungi, and parasites, including multidrug-resistant organisms.
Provectus Biopharmaceuticals (OTCQB: PVCT) ha lanciato VisiRose, Inc., il suo primo Entità Fondato, concentrandosi sulla commercializzazione della Terapia Antimicrobica Fotodinamica con Rosso Bengalese (RB PDAT) per il trattamento della cheratite infettiva e delle gravi infezioni oculari. L'Università di Miami è un azionista di minoranza in VisiRose.
Il trattamento combina il principio attivo Rosso Bengalese Sodico (RBS) di grado farmaceutico di Provectus con un dispositivo medico basato sulla luce sviluppato presso il Centro di Biophysics Oculare dell'Istituto Oftalmico Bascom Palmer. La RB PDAT è progettata per trattare le infezioni oculari causate da batteri, funghi e parassiti, inclusi gli organismi multidrug-resistant.
Provectus Biopharmaceuticals (OTCQB: PVCT) ha lanzado VisiRose, Inc., su primera Entidad Fundada, enfocándose en la comercialización de la Terapia Antimicrobiana Fotodinámica con Rosa Bengalí (RB PDAT) para tratar la queratitis infecciosa y las serias infecciones oculares. La Universidad de Miami es un accionista minoritario en VisiRose.
El tratamiento combina el ingrediente activo Rosa Bengalí Sódico (RBS) de grado farmacéutico de Provectus con un dispositivo médico basado en luz, desarrollado en el Centro de Biofísica Oftálmica del Instituto Oftálmico Bascom Palmer. La RB PDAT está diseñada para tratar infecciones oculares causadas por bacterias, hongos y parásitos, incluidos los organismos multirresistentes.
Provectus Biopharmaceuticals (OTCQB: PVCT)는 감염성 각막염과 심각한 안구 감염 치료를 위한 로즈 벵갈 광역학 항균 요법(RB PDAT)의 상업화를 목표로 하는 첫 번째 설립된 법인 VisiRose, Inc.를 출시했습니다. 마이애미 대학교는 VisiRose의 소수 주주입니다.
이 치료법은 Provectus의 제약 등급 로즈 벵갈 나트륨(RBS) API와 Bascom Palmer Eye Institute의 안과 생물물리학 센터에서 개발한 빛 기반 의료 기기를 결합합니다. RB PDAT는 다제내성 균주를 포함한 세균, 곰팡이 및 기생충으로 인해 발생하는 안구 감염을 치료하도록 설계되었습니다.
Provectus Biopharmaceuticals (OTCQB: PVCT) a lancé VisiRose, Inc., sa première entité fondée, axée sur la commercialisation de la thérapie antimikrobienne photodynamique au rose bengal (RB PDAT) pour traiter la kératite infectieuse et les infections oculaires graves. L'Université de Miami est un actionnaire minoritaire de VisiRose.
Ce traitement combine l'ingrédient actif rose bengal sodique (RBS) de qualité pharmaceutique de Provectus avec un dispositif médical basé sur la lumière développé au Centre de biophysique oculaire de l'Institut Bascom Palmer. La RB PDAT est conçue pour traiter les infections oculaires causées par des bactéries, des champignons et des parasites, y compris des organismes multirésistants.
Provectus Biopharmaceuticals (OTCQB: PVCT) hat VisiRose, Inc. gegründet, seine erste gegründete Einheit, die sich auf die Kommerzialisierung der Rosenbengal-Fotodynamischen Antimikrobiellen Therapie (RB PDAT) zur Behandlung von infektiöser Keratitis und schweren Augeninfektionen konzentriert. Die Universität von Miami ist ein Minderheitsaktionär von VisiRose.
Die Behandlung kombiniert den pharmazeutischen Wirkstoff Rosenbengal-Natron (RBS) von Provectus mit einem lichtbasierten medizinischen Gerät, das im Ophthalmic Biophysics Center des Bascom Palmer Eye Institute entwickelt wurde. Die RB PDAT ist darauf ausgelegt, Augeninfektionen zu behandeln, die durch Bakterien, Pilze und Parasiten verursacht werden, einschließlich multiresistenter Organismen.
- Creation of new clinical-stage biotechnology company focused on eye care market
- Partnership with prestigious University of Miami as minority shareholder
- Development of innovative non-invasive treatment for multidrug-resistant eye infections
- Potential value creation for stockholders through spinoff strategy
- Early clinical stage development status implies significant time and investment before potential commercialization
- No immediate revenue generation from the new entity
KNOXVILLE, Tenn., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today the launch of VisiRose, Inc. (“VisiRose”), Provectus’s first Founded Entity. This new clinical-stage biotechnology company is focused on commercializing Rose Bengal Photodynamic Antimicrobial Therapy (“RB PDAT”) for the treatment of infectious keratitis and other serious eye infections using Provectus’s bioactive synthetic small molecule and active pharmaceutical ingredient (“API”) Rose Bengal Sodium (RBS). The University of Miami (the “University”) is a minority equity shareholder of VisiRose.
RB PDAT, a groundbreaking, non-invasive investigational treatment for eye infections, is based on innovative ocular research from the Ophthalmic Biophysics Center at Bascom Palmer Eye Institute (“BPEI”) of the University’s Miller School of Medicine. RB PDAT combines a formulation of Provectus’s pharmaceutical-grade RBS API and OBC’s light-based medical device to treat eye infections caused by bacteria, fungi, and parasites, including multidrug-resistant organisms.
Dominic Rodrigues, Acting Chief Executive Officer of VisiRose, who is also President and Vice Chairman of the Board of Directors of Provectus, said, “RB PDAT represents a consequential solution for patients at risk of vision loss from infectious keratitis. We believe this innovative therapy combines precise infection-fighting capabilities with vision-preserving benefits, paving the way for a brighter future for those struggling with this challenging condition.”
Ed Pershing, Chairman of the Boards of Directors of VisiRose and Provectus added, “VisiRose exemplifies Provectus’s forward-thinking business model, bridging innovation and impact. Spinning off this clinical-stage, ophthalmology-focused entity enhances our ability to address unmet medical needs while unlocking value for our stockholders. By focusing on a high-growth area like eye care, we are both advancing RB PDAT and maximizing the intrinsic value of RBS and, ultimately, Provectus’s market position.”
A copy of VisiRose’s press release from December 10, 2024 of its launch may be found here: https://www.accesswire.com/952319/visirose-introduces-revolutionary-therapy-for-severe-eye-infections.
VisiRose’s website is accessible here: https://visirose.com/.
About VisiRose
VisiRose is a newly launched clinical-stage biotechnology company of the University of Miami and Provectus Biopharmaceuticals, focused on commercializing the Miller School of Medicine’s Bascom Palmer Eye Institute and its Ophthalmic Biophysics Center’s innovative ocular research using Provectus’s bioactive synthetic small molecule Rose Bengal Sodium (“RBS”). For more information, please visit https://visirose.com.
About Bascom Palmer Eye Institute
Bascom Palmer Eye Institute serves as the Department of Ophthalmology for the University of Miami Miller School of Medicine. The mission of BPEI is to enhance the quality of life by improving sight, preventing blindness, and advancing ophthalmic knowledge through compassionate patient care and innovative research. For 2024-2025, U.S. News & World Report (“U.S. News”) ranked BPEI as the nation’s best in ophthalmology, marking the 23rd time and 21st consecutive year that BPEI has received the No. 1 ranking since U.S. News began surveying American physicians for its annual “Best Hospitals” rankings 35 years ago.
About Provectus
Provectus Biopharmaceuticals is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of bioactive synthetic small molecules called halogenated xanthenes. The Company’s lead molecule is RBS. Provectus’s small molecule drug platform includes:
- Clinical development programs in oncology, dermatology, and ophthalmology,
- In vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers, and
- In vitro discovery programs in infectious diseases, tissue regeneration and repair, and several proprietary targets.
Information about the Company’s clinical trials can be found at the National Institutes of Health registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at www.provectusbio.com.
Forward Looking Statements
The information in this press release may include “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including those described in Item 1A of Provectus’s:
- Annual Report on Form 10-K for the period ended December 31, 2023, and
- Quarterly Report on Form 10-Q for the period ended September 30, 2024.
Contacts:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
hraines@pvct.com
(866) 594-5999
VisiRose, Inc.
Dominic Rodrigues
Acting Chief Executive Officer
rodrigues@visirose.com
(866) 216-7333
Investor Relations & Media
Provectus: Alliance Advisors Investor Relations
Alyssa Barry
alyssa@irlabs.ca
(833) 947-5227
FAQ
What is VisiRose's RB PDAT treatment for eye infections?
How will the VisiRose spinoff affect PVCT shareholders?
What is the ownership structure of VisiRose?
What types of eye infections can VisiRose's RB PDAT treat?
